## Request for Proposals (RFP): Janssen Biotech, Inc.

Funding is available to support innovative and interactive nationwide certified medical education (CME) educational programs that is designed to inform healthcare providers about current and emerging treatment options for patients with multiple myeloma.

## **Grant Application Deadline: October 10, 2021**

**Therapeutic Area:** Multiple Myeloma

**Treatment Focus:** Overall the learning objectives will focus on education on treatment and

management of patients with multiple myeloma. This will include:

• Discussion of the treatment guidelines

• Discussion of emerging standard of care for frontline therapy

• Choosing treatment endpoints (CR, MRD, etc.) and deciding upon duration of therapy

• Optimal combination regimens (triplets, quadruplets) in earlier lines of therapy

• Sequencing therapies in multiple myeloma

• Advances in treatment administration (e.g., subcutaneous, rapid IV

infusion)

**Delivery Format:** Interactive: case-based, workshops, grand rounds, dinner meetings,

regional meetings, small group discussion, ask the expert, etc. with an

enduring component (i.e., whitepaper, audio, webcast, etc.)

Target Audience: Academic Oncologists, Community Oncologists, Allied Health

Professionals, and Advanced Practice Providers

**Timelines:** Program Start Date: Q1 2022

**Funding Requirements:** Multi-support programs

**Eligibility** 

**Criteria:** CME/CE applicants must fall into one of the following categories with a

bona fide interest in hematology/oncology or other specialties:

Academic institutions (medicine, pharmacy or nursing)

Teaching hospitals Medical societies

Professional associations Government agencies

Medical education companies (accredited)

**Submission Link:** Submissions to Janssen Oncology can be completed online at:

https://www.janssen.com/us/grants-and-giving/educational-

grants/oncology

**Special Note:** Please indicate that the proposal is in response to **RFP-MM-10** in the title. Due to the ongoing COVID-19 pandemic, it is encouraged that proposals include contingency plans for virtual delivery. Program may include both live and virtual programs.

For any questions related to this RFP, please email OncologyGrants@its.jnj.com.